LACTOLOGY FOUNDATION

Palonosetron (ATC A04AA05) is a second‑generation selective 5‑HT3 receptor antagonist used for prevention and treatment of chemotherapy‑ and surgery‑induced nausea and vomiting, with no established safety for breastfeeding and a prevailing recommendation to interrupt lactation during therapy.medpedia.framar+3

ATC class and members

The ATC subgroup A04AA comprises serotonin 5‑HT3 receptor antagonists used as antiemetics, including ondansetron (A04AA01), granisetron (A04AA02), tropisetron (A04AA03), dolasetron (A04AA04) and palonosetron (A04AA05).ncbi.nlm.nih+1
Palonosetron A04AA05 is currently the only compound in this fifth position and is classified pharmacotherapeutically as an antiemetic, serotonin (5‑HT3) antagonist.europa+2

Pharmacology and mechanism

Palonosetron is a highly selective 5‑HT3 receptor antagonist with strong binding affinity to these receptors and negligible affinity for other receptor types.drugbank+1
It blocks serotonin‑mediated activation of 5‑HT3 receptors on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone, thereby inhibiting acute emesis pathways.inhrr+2

Clinical indications

Palonosetron is indicated for prevention of acute and delayed chemotherapy‑induced nausea and vomiting associated with moderately and highly emetogenic antineoplastic regimens in adults, and in many product labels also in paediatric patients ≥1 month.botplusweb.farmaceuticos+2
In some formulations it is also indicated for prevention of postoperative nausea and vomiting in adults, reflecting its prolonged antiemetic action.ameripharmaspecialty+1

Dosage and administration

A typical adult dose is 250 micrograms (0.25 mg) palonosetron administered as a single intravenous injection approximately 30 minutes before the start of chemotherapy, injected over at least 30 seconds.medpedia.framar+2
Paediatric dosing is weight‑based, commonly 20 micrograms/kg IV with a maximal total dose of 1500 micrograms, given as a slow infusion before chemotherapy.inhrr+2

General contraindications and precautions

Palonosetron is contraindicated in patients with known hypersensitivity to palonosetron or any excipients.europa+2
Caution is advised in patients with constipation or intestinal obstruction and in those receiving concomitant medicinal products that prolong the QT interval, due to class‑related potential for QT prolongation.ncbi.nlm.nih+2

Common adverse effects

Frequently reported adverse reactions include headache, constipation, dizziness and allergic manifestations such as rash or pruritus.botplusweb.farmaceuticos+2
Less frequent effects can involve sleep disturbances, tachycardia or bradycardia, transient visual changes, vasodilation, hiccups and appetite changes.medpedia.framar+2

Toxicological profile

Palonosetron has a wide therapeutic index, and acute toxicity in clinical practice is low; overdose is rare and managed with supportive and symptomatic measures.europa+1
The principal toxicological concerns relate to potential cardiovascular effects (QT interval prolongation, arrhythmias) and severe hypersensitivity reactions, especially in predisposed patients or with interacting drugs.labeling.pfizer+2

Use in pregnancy

Human data on palonosetron use during pregnancy are very limited; product information generally advises avoiding use unless clearly necessary, due to insufficient evidence of fetal safety.laegemiddelstyrelsen+2
When the clinical situation requires an antiemetic in pregnant women, benefit–risk assessment should consider alternative agents with more established pregnancy safety data.sps+1

Lactation‑specific safety

There are no direct data on excretion of palonosetron into human breast milk, and most regulatory documents state that it is unknown whether the drug is present in breast milk.fimea+2
Consequently, the prevailing recommendation in SmPCs and risk‑management summaries is to discontinue breastfeeding during palonosetron therapy, particularly when no safer alternative antiemetic is available.vademecum+2

Lactological risk assessment

From a toxicological‑lactological perspective, the absence of human milk concentration data, combined with systemic exposure and long elimination half‑life, prevents reliable estimation of infant dose and risk.e-lactancia+1
Given the antiemetic benefit in oncology and perioperative settings but the uncertain infant safety, palonosetron is best classified as “use only if strictly necessary; breastfeeding should be interrupted for the duration of treatment, with preference for alternative antiemetics when feasible.”laegemiddelstyrelsen+1

Practical lactation management

If palonosetron must be administered to a breastfeeding mother, healthcare professionals should advise temporary cessation of breastfeeding with maintenance of milk production by pumping and discarding milk until the drug is cleared.laegemiddelstyrelsen+1
Clinical decisions should integrate maternal oncologic or perioperative needs, availability of other antiemetics with known lactation safety, and the feasibility of short‑term formula or donor milk substitution.e-lactancia+1

Web‑page style monograph structure

On a dedicated toxicological‑lactological database page, the monograph for A04AA05 palonosetron can be structured into clearly labelled sections: ATC classification, mechanism of action, indications, dosage, contraindications, adverse effects, toxicology, pregnancy, lactation risk and practical breastfeeding recommendations, as outlined above.inhrr+1
This layout supports rapid clinical consultation while preserving consistent terminology and harmonised risk categories across all 5‑HT3 antagonists in the A04AA subgroup.ncbi.nlm.nih+1